https://fightcolorectalcancer.org/fight/treatment/

New Post Public Reply Private Reply Replies (1) Message Board
trding trding #5878
616
https://fightcolorectalcancer.org/fight/treat...ent-stage/

Treatments by stage

STAGE 0 AND STAGE I COLON CANCER
Patients diagnosed with stage 0 and stage I colon cancer are often cured by the surgery that removes the cancerous polyps or tumor.

STAGE 0 (IN SITU) COLON CANCER
Surgery is often the recommended treatment for stage 0 colon cancer.

Polypectomy — snaring and removing polyps containing cancer during a colonoscopy
Local excision — removal of flat colon growths “piecemeal” during colonoscopy
Open abdominal surgery — remove cancer, part of colon, and nearby lymph nodes in high risk situations

STAGE I COLON CANCER
For stage I colon cancer, surgery is also often the recommended treatment. It will typically be either:

Colectomy (resection) — removal of all or part of your colon through one incision
Laparoscopic colectomy — when a surgeon makes a few small incisions in your abdomen through which they pass a tiny camera and tools to access your colon
Medically reviewed by Dr. Al Benson, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 9/23/13

STAGE I RECTAL CANCER
There are a variety of different surgeries used to treat stage I rectal cancer:

Local excision through the anus
Low anterior resection (LAR) for tumors that are high enough in the rectum to permit reconnecting the colon or rectum to the anus (anastomosis)
Abdominoperineal resection with permanent colostomy when the distance between tumor and anus is too short to allow safe anastomosis
Possible Chemotherapy
If the tumor has gone through the outer layer of the rectum (T3) or there are cancer cells in lymph nodes (N1 or N2), then follow-up chemotherapy and chemoradiation may be recommended.

Possible Watch and Wait
For some stage I rectal cancers, there may be the option to watch and wait.

STAGE II COLON CANCER
Initial treatment for stage II colon cancer is surgery to remove the section of colon that contains the tumor and surrounding tissue with its blood vessels and lymph nodes. It could be either:

Open colectomy — when a surgeon makes a long incision in your abdomen so that they can access your colon
Laparoscopic colectomy — when a surgeon makes a few small incisions in your abdomen through which they pass a tiny camera and tools to access your colon
Chemotherapy
Treatment of node-negative stage II colon cancer is controversial. While surgery to remove the tumor in the colon is universally accepted as an initial treatment, the value of chemotherapy after that surgery (adjuvant chemotherapy) to keep cancer from recurring (coming back) is hard for patients and doctors to judge.

It’s estimated that between 4-5 percent of patients with stage II colon cancer will benefit from chemotherapy. However, there are side effects, some severe, associated with chemotherapy.

Clinical Trials
There are often clinical trials available for stage II colon cancer patients.

Medically reviewed by Dr. Al Benson, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 9/23/13

STAGE II RECTAL CANCER
For patients who are medically fit and able to undergo combined methods of therapy, treatment for stage II and III rectal cancer may consist of:

Chemoradiation before surgery
Abdominal surgery
Adjuvant chemotherapy
Patients with medical issues that make chemoradiation difficult may go directly to surgery, followed by:

No further treatment if their tumor hasn’t spread through the rectal wall or to lymph nodes
A reconsideration of adjuvant chemotherapy and chemoradiation if there is spread through the wall (T3) or into lymph nodes (N1 or N2)

STAGE III COLON CANCER
Most stage III colon cancer patients will receive a recommendation of surgery, colostomy, chemotherapy and possibly radiation.

Combination Chemotherapy
Patients who are able to tolerate combination chemotherapy that includes Eloxatin® are often prescribed:

Folfox — combination treatment with infusional 5-FU (fluorouracil), leucovorin, and oxaliplatin
Flox — combination with bolus 5-FU, leucovorin, and oxaliplatin. Severe diarrhea is more common with Flox than Folfox but outcomes are similar.
(“Bolus dose” is the administration of a medication that is given to raise its concentration in the blood to an effective level.)

Alternative Chemotherapy
Patients who have medical reasons not to use combination chemotherapy may be prescribed:

Xeloda® (capecitabine) — oral “prodrug” which is converted to 5-FU in the tissues
5-FU and leucovorin
Your doctor can discuss the advantages and disadvantages of the different chemotherapy regimens for your individual needs.

Radiation
If surgery reveals the tumor has spread outside the colon, follow-up radiation may be recommended. Radiation is not routine for stage III colon cancer.

Clinical Trials
There are often clinical trials available for stage III colon cancer.

STAGE III RECTAL CANCER
Most stage III rectal cancer patients will receive a recommendation of surgery, chemotherapy and chemoradiation combinations.

Surgery
For rectal cancer, abdominal surgery is often required to remove tumors. You may be treated with radiation and/or chemotherapy before surgery.

Low Anterior Resection (LAR)
Abdominoperineal Resection (APR)
Chemotherapy Combinations
For stage III rectal cancer patients who are medically fit and can tolerate combined methods of therapy, treatment can consist of chemoradiation (chemotherapy and radiation) before surgery (adjuvant therapy), abdominal surgery, and/or adjuvant chemotherapy after surgery.

Patients who cannot tolerate chemoradiation at first, may go directly to surgery with no additional treatment, and then onto adjuvant chemotherapy and/or chemoradiation after surgery.

For a list of chemoradiation options, adjuvant chemotherapy options, and adjuvant chemotherapy options (a “sandwich” of chemo-chemoradiation-chemo), download Your Guide in the Fight.

STAGE IV, METASTATIC CANCER OR RECURRENT CRC
Treatment for stage IV or recurrent colorectal cancer is complex, and generally requires consultation with medical, surgical and radiological doctors. For a list of questions to ask if you have stage IV or recurrent CRC, and for examples of treatment options combined to treat metastatic disease over time, download Your Guide in the Fight.

Take time to get the best information and advice possible from a multidisciplinary team. This process is vitally important. Make sure to get a second opinion, even if it takes extra time.

Surgery
If the liver, lungs, or the lining of the abdomen (peritoneum) are affected, you may undergo multiple surgeries to remove metastatic disease. Often, chemotherapy and radiation are combined with surgery to shrink tumors.

Partial Hepatectomy — also known as a liver resection, this surgery is intended to remove tumors from the liver
Pulmonary Metastasectomy — a surgery where tumors which have metastasized to the lung are removed
Chemoembolization Surgery — sometimes called transarterial chemoembolization (TACE), it is a combination of an embolization procedure (a procedure that reduces blood flow to the liver) and chemotherapy
Hyperthermic Intraperitoneal Chemotherapy — also called HIPEC, this surgery involves filling the abdominal cavity with heated chemotherapy drugs
Chemotherapy Combinations
There are a variety of chemotherapy combinations that may be prescribed.

Capox or Xelox — Capecitabine (Xeloda®) plus oxaliplatin (Eloxatin®). Capecitabine is an oral drug that works the same way as 5-FU inside the cancer cell.
Folfox — 5-FU, Oxaliplatin (Eloxatin®), and Leucovorin
Folfiri — 5-FU, Irinotecan (Camptosar®), and Leucovorin
These regimens may be combined with targeted therapies such as bevacizumab (Avastin®), cetuximab (Erbitux®), or panitumumab (Vectibix®).

Patients who are not able to tolerate intensive therapy have other options. Doctors may recommend:

5-FU plus leucovorin with or without bevacizumab (Avastin®)
Capecitabine (Xeloda®) with or without bevacizumab (Avastin®)
Treatment with capectiabine (Xeloda®) alone should only be considered a reasonable option for selected patients who are not candidates for more aggressive combination regimens with oxaliplatin (Eloxatin®) or irinotecan (Camptosar®).

Other Options
Patients who have stopped responding to other treatments or who cannot receive certain chemotherapy medicines have other options, like trifluridine and tipiracil (Lonsurf®), a nucleoside-analogue drug.

Targeted Therapies
There are approved targeted therapies for colorectal cancer, including:

Cetuximab (Erbitux®)
Panitumumab (Vectibix®)
Bevacizumab (Avastin®)
Ziv-aflibercept (Zaltrap®)
Regorafenib (Stivarga®)
Ramucirumab (Cyramza®)
Vemurafenib (Zelboraf ®)
Immunotherapies
Immunotherapy uses certain parts of a person’s immune system to fight disease. Immunotherapy for colorectal cancer has been shown to be effective in a small subset of patients with a certain biomarker, microsatellite-instability (MSI) or mismatch repair deficiency (MMR). All colorectal patients should know their MSI/MMR status!

Pembrolizumab (Keytruda ®)
This is an option for patients who have the microsatellite instable-high (MSI-H) or deficient mismatch repair (d-MMR) biomarkers. This treatment is indicated for adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having a MSI-H or dMMR biomarker, including patients with solid tumors that have progressed following prior treatment and who have no alternative treatment options.

Nivolumab (Opdivo ®)
This therapy is for use in microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). Nivolumab has been approved for mCRC patients whose cancer either progressed after being treated with a fluoropyrimidine, oxaliplatin, and irinotecan, or did not respond to those treatments.

Ipilimumab (Yervoy®)
This drug may be used in combination with nivolumab as a treatment option for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer following the progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Colorectal cancer treatment by stage can be straightforward in the early stages, but it can become incredibly complicated once the cancer progresses. Our Guide in the Fight includes more detailed colorectal cancer treatment by stage for stage III, IV and recurrent cancers.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AB SKF to Hold EGM, Spin Off Automotive Assets

Updated Category News Views 5

SKF's Extraordinary Meeting: A Pivotal Moment AB SKF, a heavyweight in the industrial technology sector, is summoning its shareholders for an Extraordinary General Meeting on October 1, 2026. The venue? The Elite Park Avenue Hotel in Gothenburg, Sweden—sounds fancy, but don't expect to hear a string quartet at this shindig. What's truly on the agenda is a critical...

Continue Reading
DoorDash Speeds Up Gifting: Same-Day Delivery Wins

Updated Category News Views 1

Transforming Urgent Gift-Giving with Local Delivery Ever found yourself scrambling for a last-minute gift when time seems to be slipping away? That's where DoorDash steps up, changing the game with their same-day delivery options. In the fast-paced world we're living in, folks aren't just leaning on DoorDash for takeout anymore. They're pushing it as a lifeline for...

Continue Reading
CABP Market Sees Potential in New Treatments Rising

Updated Category News Views 2

Rising Threats and New Solutions in CABP Market Listen up, folks. The community-acquired bacterial pneumonia (CABP) market is set to swell. And why is that? Well, it's got everything to do with a growing disease burden, aging populations, and complications from comorbid conditions. But here's the kicker: antimicrobial resistance is climbing like a cat up a tree, and that...

Continue Reading
U.S. Court Ruling Opens Market for Cocrystal's CrysQnol™

Updated Category News Views 9

Legal Drama Clears Market Path Well, folks, here’s a win from the trenches for Cocrystal Tech that can shake up the nutraceutical market. Kaneka's grip on the patent for their ubiquinol concoctions just got busted by the U.S. District Court. They ruled that Kaneka's claims lacked utility and enablement, essentially saying they were pitching an untested hypothesis as an...

Continue Reading
Wooree Group Pushes for Rigorous Liposome Standards

Updated Category News Views 1

Rallying for Rigorous Scientific Validation Ever find yourself pondering how many so-called 'innovative' health products really deliver what they promise? Let me tell ya, Wooree Group’s CEO, Ji-yong Yoon, ain’t buying into flimsy claims. At the Vitafoods Asia 2026 event in Bangkok, Yoon sent a clear message: Without scientific validation, calling a product 'liposomal'...

Continue Reading
Interventional Ophthalmology: Early Eye Care Strategies Evolve

Updated Category News Views 2

Proactive Eye Care: The New Frontier Today's eye care landscape is all about catching things early, folks. Long gone are the days of waiting for eyesight to deteriorate before rushing to the nearest eye doc. In Racine, interventional ophthalmology is shifting gears towards preventive care—looking ahead to stop eye diseases in their tracks before they muck up a person's...

Continue Reading
Dentsply Sirona Faces Insider Troubles: An Investor Call

Updated Category News Views 3

Are Dentsply Sirona Insiders on Thin Ice? The stock market's a tumultuous sea, and right now, it seems like some of those at the helm of Dentsply Sirona Inc. might be rocking the boat a bit too much. Let me tell you, navigating these corporate storms isn't for the faint-hearted. The latest noise coming from Halper Sadeh LLC suggests that some directors and officers over...

Continue Reading
SKF's Automotive Arm Set for Stockholm Debut in Dec

Updated Category News Views 4

The Big Spin-Off Play: SKF Vertevo So, SKF is at it again, pushing their Automotive business out the door as a newly minted public company—SKF Vertevo—on the horizon. It's like watching a mother bird kick the fledgling out of the nest. The Board's cooked up this spin-off strategy, and they're eyeing the Nasdaq Stockholm as the breeding ground, with the gears all set...

Continue Reading
Huayan Robotics Hits IMTS 2026 with Cutting-Edge Tech

Updated Category News Views 2

Unveiling Robotics Prowess at IMTS 2026 Every two years, the world of manufacturing gathers at the International Manufacturing Technology Show (IMTS), and this time, the spotlight is on Huayan Robotics. With the event drawing over 90,000 professionals, everybody with a finger on the pulse of intelligent manufacturing will be keen to see what Huayan has up its sleeve. This...

Continue Reading
Stem Cell Market Set for Major Gains to 2031

Updated Category News Views 1

Stem Cells: The Next Frontier or Hype? Folks, stem cells are no longer just a sci-fi concept tucked away in lab coats. This sector's set to boom from USD 18.9 billion in 2026 to a whopping USD 32.57 billion by 2031. Yeah, you heard it right, a solid 11.5% compound annual growth rate. Now, whether you're an investor or just keeping your finger on the biotech pulse, there's...

Continue Reading

Top 5 Most Recently Viewed Articles

Joey Bosa's $12.6M Deal and His Future Beyond the NFL

Updated Category News Views 484

Joey Bosa: A Star on the Field and in Business Joey Bosa is making headlines not just for his performance on the football field but also for his impressive off-field ventures. With the announcement of a new contract, he is poised for a thrilling season ahead. A New Chapter with the Buffalo Bills Recently, Bosa secured a lucrative one-year deal valued at $12.6 million with...

Continue Reading
Tesla's Vision for the Future of Autonomous Transportation

Updated Category News Views 259

The Exciting Future of Tesla's Autonomous Vehicles The recent unveiling by Tesla has stirred excitement and curiosity among both fans and investors. At a vibrant event, Elon Musk showcased Tesla's ambitious vision for the future of transportation with the introduction of their long-anticipated driverless robotaxis. This presentation had every characteristic of Musk's...

Continue Reading
Ask Hercules: New Tool Boosts AI Visibility for SMBs

Updated Category News Views 19

AI Visibility: The New Frontier for SMBs There's a new name in town aiming to make sure small and midsize businesses aren't left in the dust of the AI revolution. Muse Platforms just launched Ask Hercules, an AI visibility platform that gives businesses, creators, and thought leaders a chance to assess and improve how they show up on AI platforms like ChatGPT, Claude, and...

Continue Reading
Transforming $100 into $343: A Look at ServiceNow's Growth

Updated Category News Views 68

How a $100 Investment in ServiceNow Could Transform Your Finances ServiceNow (NYSE: NOW) has shown remarkable performance in the stock market over the past five years, demonstrating an annualized return of 27.51%. Impressively, this places its overall growth at 13.52% above market averages. The Current Market Capitalization As it stands, ServiceNow boasts a substantial...

Continue Reading
Gladstone Land Faces Market Challenges as Stock Reaches Low

Updated Category News Views 426

Market Challenges for Gladstone Land Corporation In a rapidly evolving economic landscape, Gladstone Land Corporation (NASDAQ: LAND) has recently encountered hurdles as its stock dipped to a 52-week low, reaching a price of $10.44. This decline highlights the stock's turbulent journey over the past year, where it has decreased by approximately 27.82%. With a market...

Continue Reading